||The lead section of this article may need to be rewritten. (August 2013)|
|Classification and external resources|
Fluorescent micrographs (100x) of Wallerian degeneration in cut and crushed peripheral nerves. Left column is proximal to the injury, right is distal. A and B: 37 hours post cut. C and D: 40 hours post crush. E and F: 42 hours post cut. G and H: 44 hours post crush.
Wallerian degeneration is a process that results when a nerve fiber is cut or crushed, in which the part of the axon separated from the neuron's cell body degenerates distal to the injury. This is also known as anterograde or orthograde degeneration. A related process known as 'Wallerian-like degeneration' occurs in many neurodegenerative diseases, especially those where axonal transport is impaired. Primary culture studies suggest that a failure to deliver sufficient quantities of the essential axonal protein NMNAT2 is a key initiating event.
Wallerian degeneration occurs after axonal injury in both the peripheral nervous system (PNS) and central nervous system (CNS). It occurs in the axon stump distal to a site of injury and usually begins within 24–36 hours of a lesion. Prior to degeneration, distal axon stumps tend to remain electrically excitable. After injury, the axonal skeleton disintegrates, and the axonal membrane breaks apart. The axonal degeneration is followed by degradation of the myelin sheath and infiltration by macrophages. The macrophages, accompanied by Schwann cells, serve to clear the debris from the degeneration.
The nerve fiber's neurolemma does not degenerate and remains as a hollow tube. Within 4 days of the injury, the distal end of the portion of the nerve fiber proximal to the lesion sends out sprouts towards those tubes and these sprouts are attracted by growth factors produced by Schwann cells in the tubes. If a sprout reaches the tube, it grows into it and advances about 1 mm per day, eventually reaching and reinnervating the target tissue. If the sprouts cannot reach the tube, for instance because the gap is too wide or scar tissue has formed, surgery can help to guide the sprouts into the tubes. This regeneration is much slower in the spinal cord than in PNS. The crucial difference is that in the CNS, including in the spinal cord, myelin sheaths are produced by oligodendrocytes and not by Schwann cells.
Wallerian degeneration is named after Augustus Volney Waller. Waller experimented on frogs in 1850, by severing their glossopharyngeal and hypoglossal nerves. He then observed the distal nerves from the site of injury, which were separated from their cell bodies in the brain stem. Waller described the disintegration of myelin, which he referred to as "medulla", into separate particles of various sizes. The degenerated axons formed droplets that could be stained, thus allowing studies of the course of individual nerve fibres.
Although most injury responses include a calcium influx signaling to promote resealing of severed parts, axonal injuries initially lead to acute axonal degeneration (AAD), which is rapid separation of the proximal (the part nearer the cell body) and distal ends within 30 minutes of injury. Degeneration follows with swelling of the axolemma, and eventually leads to bead like formation. The process takes about roughly 24 hours in the PNS, and longer in the CNS. The signaling pathways leading to axolemma degeneration are currently unknown. However, research has shown that this AAD process is calcium–independent.
Granular disintegration of the axonal cytoskeleton and inner organelles occurs after axolemma degradation. Early changes include accumulation of mitochondria in the paranodal regions at the site of injury. Endoplasmic reticulum degrades and mitochondria swell up and eventually disintegrate. The depolymerization of microtubules occurs and is soon followed by degradation of the neurofilaments and other cytoskeleton components. The disintegration is dependent on Ubiquitin and Calpain proteases (caused by influx of calcium ion), suggesting that axonal degeneration is an active process and not a passive one as previously misunderstood. Thus the axon undergoes complete fragmentation. The rate of degradation is dependent on the type of injury and is also slower in the CNS than in the PNS. Another factor that affects degradation rate is the diameter of the axon: larger axons require a longer time for the cytoskeleton to degrade and thus take a longer time to degenerate.
Myelin is a phospholipid membrane that wraps around axons to provide them with insulation. It is produced by Schwann cells in the PNS, and by oligodendrocytes in the CNS. Myelin clearance is the next step in Wallerian degeneration following axonal degeneration. The cleaning up of myelin debris is different for PNS and CNS. PNS is much faster and efficient at clearing myelin debris in comparison to CNS, and Schwann cells are the primary cause of this difference. Another key aspect is the change in permeability of the blood-tissue barrier in the two systems. In PNS, the permeability increases throughout the distal stump, but the barrier disruption in CNS is limited to just the site of injury.
Clearance in PNS
The response of Schwann cells to axonal injury is rapid. The time period of response is estimated to be prior to the onset of axonal degeneration. Neuregulins are believed to be responsible for the rapid activation. They activate ErbB2 receptors in the Schwann cell microvilli, which results in the activation of the mitogen-activated protein kinase (MAPK). Although MAPK activity is observed, the injury sensing mechanism of Schwann cells is yet to be fully understood. The sensing is followed by decreased synthesis of myelin lipids and eventually stops within 48 hrs. The myelin sheaths separate from the axons at the Schmidt-Lanterman incisures first and then rapidly deteriorate and shorten to form bead-like structures. Schwann cells continue to clear up the myelin debris by degrading their own myelin, phagocytose extracellular myelin and attract macrophages to myelin debris for further phagocytosis. However, the macrophages are not attracted to the region for the first few days; hence the Schwann cells take the major role in myelin cleaning until then.
Schwann cells have been observed to recruit macrophages by release of cytokines and chemokines after sensing of axonal injury. The recruitment of macrophages helps improve the clearing rate of myelin debris. The resident macrophages present in the nerves release further chemokines and cytokines to attract further macrophages. The degenerating nerve also produce macrophage chemotactic molecules. Another source of macrophage recruitment factors is serum. Delayed macrophage recruitment was observed in B-cell deficient mice lacking serum antibodies. These signaling molecules together cause an influx of macrophages, which peaks during the third week after injury. While Schwann cells mediate the initial stage of myelin debris clean up, macrophages come in to finish the job. Macrophages are facilitated by opsonins, which label debris for removal. The 3 major groups found in serum include complement, pentraxins, and antibodies. However, only complement has shown to help in myelin debris phagocytosis.
Murinson et al. (2005) observed that non-myelinated or myelinated Schwann cells in contact with an injured axon enter cell cycle thus leading to proliferation. Observed time duration for Schwann cell divisions where approximately 3 days after injury. Possible sources of proliferation signal are attributed to the ErbB2 receptors and the ErbB3 receptors. This proliferation could further enhance the myelin cleaning rates and plays an essential role in regeneration of axons observed in PNS. Schwann cells emit growth factors that attract new axonal sprouts growing from the proximal stump after complete degeneration of the injured distal stump. This leads to possible reinnervation of the target cell or organ. However, the reinnervation is not necessarily perfect, as possible misleading occurs during reinnervation of the proximal axons to target cells.
Clearance in CNS
In comparison to Schwann cells, oligodendrocytes require axon signals to survive. In their developmental stages, oligodendrocytes that failed to make contact to axon and receive any axon signals underwent apoptosis.
Experiments in Wallerian degeneration have shown that upon injury oligodendrocytes either undergo programmed cell death or enter a state of rest. Therefore, unlike Schwann cells, oligodendrocytes fail to clean up the myelin sheaths and their debris. In experiments conducted on rats , myelin sheaths were found for up to 22 months. Therefore, CNS rates of myelin sheath clearance are very slow and could possibly be the cause for hindrance in the regeneration capabilities of the CNS axons as no growth factors are available to attract the proximal axons. Another feature that results eventually is Glial scar formation. This further hinders chances for regeneration and reinnervation.
Oligodendrocytes fail to recruit macrophages for debris removal. Macrophage entry in general into CNS site of injury is very slow. In contrast to PNS, Microglia play a vital role in CNS wallerian degeneration. However, their recruitment is slower in comparison to macrophage recruitment in PNS by approximately 3 days. Further, microglia might be activated but hypertrophy, and fail to transform into fully phagocytic cells. Those microglia that do transform, clear out the debris effectively. Differentiating phagocytic microglia can be accomplished by testing for expression of Major histocompatibility complex (MHC) class I and II during wallerian degeneration. The rate of clearance is very slow among microglia in comparison to macrophages. Possible source for variations in clearance rates could include lack of opsonin activity around microglia, and the lack of increased permeability in the blood–brain barrier. The decreased permeability could further hinder macrophage infiltration to the site of injury.
These findings have suggested that the delay in Wallerian degeneration in CNS in comparison to PNS is caused not due to a delay in axonal degeneration, but rather is due to the difference in clearance rates of myelin in CNS and PNS.
Regeneration follows degeneration. Regeneration is rapid in PNS, allowing for rates of up to 1 millimeter a day of regrowth. Grafts may also be needed to allow for appropriate reinnervation. It is supported by Schwann cells through growth factors release. CNS regeneration is much slower, and is almost absent in most species. The primary cause for this could be the delay in clearing up myelin debris. Myelin debris, present in CNS or PNS, contains several inhibitory factors. The elongated presence of myelin debris in CNS could possibly hinder the regeneration. An experiment conducted on Newts, animals that have fast CNS axon regeneration capabilities, found that Wallerian degeneration of an optic nerve injury took up to 10 to 14 days on average, further suggesting that slow clearance inhibits regeneration.
Schwann cells and endoneural fibroblasts in PNS
In healthy nerves, Nerve growth factor (NGF) is produced in very small amounts. However, upon injury, NGF mRNA expression increases by five to sevenfold within a period of 14 days. Nerve fibroblasts and Schwann cells play an important role in increased expression of NGF mRNA. Macrophages also stimulate Schwann cells and fibroblasts to produce NGF via macrophage-derived interleukin-1. Other neurotrophic molecules produced by Schwann cells and fibroblasts together include Brain-derived neurotrophic factor, Glial cell line-derived neurotrophic factor, Ciliary neurotrophic factor, Leukemia inhibitory factor, Insulin-like growth factor, and Fibroblast growth factor. These factors together create a favorable environment for axonal growth and regeneration. Apart from growth factors, Schwann cells also provide structural guidance to further enhance regeneration. During their proliferation phase, Schwann cells begin to form a line of cells called Bands of Bungner within the basal laminar tube. Axons have been observed to regenerate in close association to these cells. Schwann cells upregulate the production of cell surface adhesion molecule ninjurin further promoting growth. These lines of cell guide the axon regeneration in proper direction. The possible source of error that could result from this is possible mismatching of the target cells as discussed earlier.
Due to lack of such favorable promoting factors in CNS, regeneration is stunted in CNS.
Delayed Wallerian degeneration
Mice belonging to the strain C57BL/Wlds have delayed Wallerian degeneration, and, thus, allow to study the roles of various cell types and the underlying cellular and molecular processes. Current understanding of the process has been possible via experimentation on the Wlds strain of mice. The mutation occurred first in mice in Harlan-Olac, a laboratory producing animals the United Kingdom. The Wlds mutation is an autosomal-dominant mutation occurring in the mouse chromosome 4. The gene mutation is an 85-kb tandem triplication, occurring naturally. The mutated region contains two associated genes: nicotinamide mononucleotide adenlyl transferase 1 (Nmnat-1) and ubiquitination factor e4b (Ube4b). A linker region encoding 18 amino acids is also part of the mutation.< The protein created, localizes within the nucleus and is undetectable in axons.
Effects of Mutation
The mutation causes no harm to the mouse. The only known effect is that the Wallerian degeneration is delayed by up to three weeks on average after injury of a nerve. At first, it was suspected that the Wlds mutation slows down the macrophage infiltration, but recent studies suggest that the mutation protects axons rather than slowing down the macrophages. The process by which the axonal protection is achieved is poorly understood. However, studies suggest that the Wlds mutation leads to overexpression of the Nmnat-1 protein, which leads to increased NAD synthesis. This in turn activates SIRT1-dependent process within the nucleus, causing changes in gene transcription. NAD+ by itself provides added axonal protection by increasing the axon's energy resources. More recent work, however, raises doubt that either NMNAT or NAD can substitute for the full length WldS gene. These authors demonstrated by both in vitro and in vivo methods that the protective effect of overexpression of NMNAT1 or the addition of NAD did not protect axons from degeneration. Thus, the underlying biological mechanism accounting for the WldS phenotype remains unknown.
The provided axonal protection delays the onset of Wallerian degeneration. Schwann cell activation would be delayed, and they would not detect axonal degradation signals from ErbB2 receptors. In experiments on Wlds mutated mice, macrophage infiltration was considerably delayed by up to six to eight days. However, once the axonal degradation has begun, degeneration takes its normal course, and, respective of the nervous system, degradation follows at the above-described rates. Possible effects that could result due to this late onset would be weaker regenerative abilities in the mice.
- Trauma and Wallerian Degeneration, University of California, San Francisco
- Coleman, Michael P.; Freeman, Marc R. (1 June 2010). "Wallerian Degeneration, Wld, and Nmnat". Annual Review of Neuroscience 33 (1): 245–267. doi:10.1146/annurev-neuro-060909-153248. PMID 20345246.
- Gilley, Jonathan; Coleman, Michael P.; Barres, Ben A. (25 January 2010). "Endogenous Nmnat2 Is an Essential Survival Factor for Maintenance of Healthy Axons". PLoS Biology 8 (1): e1000300. doi:10.1371/journal.pbio.1000300. PMC 2811159. PMID 20126265.
- Waller, A. (1 January 1850). "Experiments on the Section of the Glossopharyngeal and Hypoglossal Nerves of the Frog, and Observations of the Alterations Produced Thereby in the Structure of Their Primitive Fibres". Philosophical Transactions of the Royal Society of London 140 (0): 423–429. doi:10.1098/rstl.1850.0021. JSTOR 108444.
- Coleman, M. P.; Conforti, L.; Buckmaster, E. A.; Tarlton, A.; Ewing, R. M.; Brown, M. C.; Lyon, M. F.; Perry, V. H. (18 August 1998). "An 85-kb tandem triplication in the slow Wallerian degeneration (Wlds) mouse". Proceedings of the National Academy of Sciences 95 (17): 9985–9990. doi:10.1073/pnas.95.17.9985. PMC 21448. PMID 9707587.
- Kerschensteiner, Martin; Schwab, Martin E; Lichtman, Jeff W; Misgeld, Thomas (9 April 2005). "In vivo imaging of axonal degeneration and regeneration in the injured spinal cord". Nature Medicine 11 (5): 572–577. doi:10.1038/nm1229. PMID 15821747.
- Vargas, Mauricio E.; Barres, Ben A. (1 July 2007). "Why Is Wallerian Degeneration in the CNS So Slow?". Annual Review of Neuroscience 30 (1): 153–179. doi:10.1146/annurev.neuro.30.051606.094354. PMID 17506644.
- Zimmerman, UP; Schlaepfer, WW (1984 Mar 10). "Multiple forms of Ca-activated protease from rat brain and muscle.". The Journal of biological chemistry 259 (5): 3210–8. PMID 6321500.
- Guertin, A. D. (30 March 2005). "Microanatomy of Axon/Glial Signaling during Wallerian Degeneration". Journal of Neuroscience 25 (13): 3478–3487. doi:10.1523/JNEUROSCI.3766-04.2005. PMID 15800203.
- Dailey, AT; Avellino, AM; Benthem, L; Silver, J; Kliot, M (1998 Sep 1). "Complement depletion reduces macrophage infiltration and activation during Wallerian degeneration and axonal regeneration.". The Journal of neuroscience : the official journal of the Society for Neuroscience 18 (17): 6713–22. PMID 9712643.
- Murinson, B. B. (2 February 2005). "Degeneration of Myelinated Efferent Fibers Prompts Mitosis in Remak Schwann Cells of Uninjured C-Fiber Afferents". Journal of Neuroscience 25 (5): 1179–1187. doi:10.1523/JNEUROSCI.1372-04.2005. PMID 15689554.
- Liu, H Mei; Yjyang, Lin Hsue; Yang, Yu Jen (1995 Jul). "Schwann cell properties: 3. C-fos expression, bFGF production, phagocytosis and proliferation during Wallerian degeneration.". Journal of neuropathology and experimental neurology 54 (4): 487–96. doi:10.1097/00005072-199507000-00002. PMID 7602323.
- Barres, B.A.; Jacobson, M.D.; Schmid, R.; Sendtner, M.; Raff, M.C. (31 July 1993). "Does oligodendrocyte survival depend on axons?". Current Biology 3 (8): 489–497. doi:10.1016/0960-9822(93)90039-Q. PMID 15335686.
- Ludwin, S. K. (31 May 1990). "Oligodendrocyte survival in Wallerian degeneration". Acta Neuropathologica 80 (2): 184–191. doi:10.1007/BF00308922. PMID 1697140.
- KOSHINAGA, MORIMICHI; WHITTEMORE, SCOTT R. (1 April 1995). "The Temporal and Spatial Activation of Microglia in Fiber Tracts Undergoing Anterograde and Retrograde Degeneration Following Spinal Cord Lesion". Journal of Neurotrauma 12 (2): 209–222. doi:10.1089/neu.1995.12.209. PMID 7629867.
- George, R; Griffin, JW (1 October 1994). "Delayed Macrophage Responses and Myelin Clearance during Wallerian Degeneration in the Central Nervous System: The Dorsal Radiculotomy Model". Experimental Neurology 129 (2): 225–236. doi:10.1006/exnr.1994.1164. PMID 7957737.
- Lundy-Ekman, Laurie. Neuroscience: Fundamentals for Rehabilitation; 3rd ed. Saunders, 2007. ISBN 978-1-4160-2578-8
- He, Zhigang; Koprivica, Vuk (21 July 2004). "The Nogo signaling pathway for regeneration block.". Annual Review of Neuroscience 27 (1): 341–368. doi:10.1146/annurev.neuro.27.070203.144340. PMID 15217336.
- Turner, James E.; Glaze, Kathleen A. (1 March 1977). "The early stages of wallerian degeneration in the severed optic nerve of the newt (Triturus viridescens)". The Anatomical Record 187 (3): 291–309. doi:10.1002/ar.1091870303. PMID 851236.
- Heumann, R.; Korsching, S; Bandtlow, C; Thoenen, H (1 June 1987). "Changes of nerve growth factor synthesis in nonneuronal cells in response to sciatic nerve transection". The Journal of Cell Biology 104 (6): 1623–1631. doi:10.1083/jcb.104.6.1623. PMID 3034917.
- Lindholm, D; Heumann, R; Hengerer, B; Thoenen, H (1988 Nov 5). "Interleukin 1 increases stability and transcription of mRNA encoding nerve growth factor in cultured rat fibroblasts.". The Journal of biological chemistry 263 (31): 16348–51. PMID 3263368.
- Thomas, PK; King, RH (1 October 1974). "The degeneration of unmyelinated axons following nerve section: an ultrastructural study.". Journal of neurocytology 3 (4): 497–512. doi:10.1007/BF01098736. PMID 4436692.
- Araki, Toshiyuki; Milbrandt, Jeffrey (31 July 1996). "Ninjurin, a Novel Adhesion Molecule, Is Induced by Nerve Injury and Promotes Axonal Growth". Neuron 17 (2): 353–361. doi:10.1016/S0896-6273(00)80166-X. PMID 8780658.
- Perry, V. H.; Brown, M. C.; Tsao, J. W. (1 October 1992). "The Effectiveness of the Gene Which Slows the Rate of Wallerian Degeneration in C57BL/Ola Mice Declines With Age". European Journal of Neuroscience 4 (10): 1000–1002. doi:10.1111/j.1460-9568.1992.tb00126.x. PMID 12106435.
- Mack, Till G.A.; Reiner, Michael; Beirowski, Bogdan; Mi, Weiqian; Emanuelli, Monica; Wagner, Diana; Thomson, Derek; Gillingwater, Tom; Court, Felipe; Conforti, Laura; Fernando, F. Shama; Tarlton, Andrea; Andressen, Christian; Addicks, Klaus; Magni, Giulio; Ribchester, Richard R.; Perry, V. Hugh; Coleman, Michael P. (19 November 2001). Nature Neuroscience 4 (12): 1199–1206. doi:10.1038/nn770. PMID 11770485.
- Araki, T. (13 August 2004). "Increased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal Degeneration". Science 305 (5686): 1010–1013. doi:10.1126/science.1098014. PMID 15310905.
- Wang, J.coauthors=Zhai, Q; Chen, Y; Lin, E; Gu, W; McBurney, MW; He, Z (25 July 2005). "A local mechanism mediates NAD-dependent protection of axon degeneration". The Journal of Cell Biology 170 (3): 349–355. doi:10.1083/jcb.200504028. PMC 2171458. PMID 16043516.
- Conforti, L; Fang, G; Beirowski, B; Wang, M S; Sorci, L; Asress, S; Adalbert, R; Silva, A; Bridge, K; Huang, X P; Magni, G; Glass, J D; Coleman, M P (28 April 2006). "NAD+ and axon degeneration revisited: Nmnat1 cannot substitute for WldS to delay Wallerian degeneration". Cell Death and Differentiation 14 (1): 116–127. doi:10.1038/sj.cdd.4401944. PMID 16645633.
- Fujiki, Minoru; Zhang, Ziyin; Guth, Lloyd; Steward, Oswald (29 July 1996). "Genetic influences on cellular reactions to spinal cord injury: Activation of macrophages/microglia and astrocytes is delayed in mice carrying a mutation (WldS) that causes delayed Wallerian degeneration". The Journal of Comparative Neurology 371 (3): 469–484. doi:10.1002/(SICI)1096-9861(19960729)371:3<469::AID-CNE9>3.0.CO;2-0. PMID 8842900.